A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 304 participants.

Also called NCT04153981

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 304 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04153981
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
India (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04153981. Allocation not applicable; no masking; primary purpose treatment. Start 2019-12-16 (actual); primary completion 2021-07-30 (actual). Results posted on 2024-02-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Insulin Glargine
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct04153981
Content hash
1b4da8e271929b20e769fc580f2250adb4507916120f8f16a2d900828caf363f